Conjunctivities of newborns

Abstract

The article is focused on the peculiarities of the clinical course of separate forms of neonatal conjunctivitis, depending on the etiological factor. It was found that more often the disease refers to nosocomial eye infection and bacterial nature. We performed the bacteriological analysis of the contents of the conjunctival cavity of 50 newborn patients being treated in the neonatal department. Our analysis indicated the leading role of gram-positive bacteria — Staph. epidermidis (59.7%) and Staph. aureus (21.7%) in the development of the inflammatory process. The share of other types of pathogens, including gram-negative minor and various pathogens, is from 0.54% to 3.2%.

The cause of nosocomial infection is considered to be the pathogen that circulates in the department and acquires the features of a hospital strain. These are consistent with the results of similar studies conducted by both domestic and foreign clinicians, which are also presented in the article. Particular attention is paid to the causative agents of intrauterine infections that are dangerous for the anterior section: gonococcus, chlamydia, herpes simplex, etc. These agents often cause serious diseases in newborns (gonoblenorrhea, ophthalmic chlamydiosis, and ophthalmic herpes), in which the cornea and vision are often affected.

The article highlights the measures of primary prevention of intrapartum infection of the ocular surface in newborns, adopted in Russia. The paper presents modern approaches to selecting drugs for local antibacterial therapy of neonatal conjunctivitis, considering age restrictions for their use. Methods of laboratory diagnostics and their validity for the etiology of conjunctivitis have been described in detail. For example, the bacteriological method (inoculations in various culture media) is considered a reference (specificity 100%). The culture medium can be used to isolate bacteria, chlamydia, and mycoplasma, which allows getting clear results even with a minimal amount of microflora

Keywords

conjunctivitis / treatment / newborns

References

[1] Ivanov DO, editor. Klinicheskie rekomendatsii (protokoly) po neonatologii. Saint Petersburg: Inform-Navigator; 2016. 462 p. (In Russ).

[2] Клинические рекомендации (протоколы) по неонатологии / под ред. Д.О. Иванова. Санкт-Петербург: Информ-Навигатор, 2016. 463 с.

[3] Rutar T. Neonatal’nyy kon”yunktivit. In: Hoyt KS, Taylor D. Paediatric ophthalmology. Moscow: Panfilov’s publishing house; 2015. P. 104–108. (In Russ).

[4] Рутар Т. Неонатальный конъюнктивит. В кн.: Хойт К.С., Тейлор Д. Детская офтальмология. Москва: Издательство Панфилова, 2015. С. 104–108.

[5] Shabalov NP. Neonatologiya. Study guide. Moscow: GEOTAR-Media; 2016. 736 p. (In Russ).

[6] Шабалов Н.П. Неонатология. Учебное пособие. Москва: ГЭОТАР-Медиа, 2016. 736 c.

[7] Arestova NN, Katargina LA, Yani EV. Conjunctivitis and dacryocystitis in the children: the clinical characteristic and modern approaches to the treatment. Russian Pediatric Ophthalmology. 2016;11(4):200-206. (In Russ). doi: 10.18821/1993-1859-2016-11-4-200-206

[8] Арестова Н.Н., Катаргина Л.А., Яни Е.В. Конъюнктивиты и дакриоциститы у детей: клиническая характеристика, современные возможности лечения // Российская педиатрическая офтальмология. 2016. T. 11, №4. С. 200–206. doi: 10/18821/1993-1859-2016-11-4-200-206

[9] Shukhov VS, Baibarina EN, Ryumina II, Zubkov VV. Antimikrobnaya terapiya u detei. Moscow: GEOTAR-Media; 2016. 314 p. (In Russ).

[10] Шухов В.С., Байбарина Е.Н., Рюмина И.И., Зубков В.В. Антимикробная терапия у детей. Москва: ГЭОТАР-Медиа, 2016. 314 с.

[11] Borer A, Livshiz-Riven I, Golan A, et al. Hospital-acquired conjunctivitis in a neonatal intensive care unit: Bacterial etiology and susceptibility patterns. Am J Infect Control. 2010;38(8):650-652. doi: 10.1016/j.ajic.2010.01.002

[12] Borer A., Livshiz-Riven I., Golan A., et al. Hospital-acquired conjunctivitis in a neonatal intensive care unit: Bacterial etiology and susceptibility patterns // Am J Infect Control. 2010. Vol. 38, N 8. P. 650-652. doi: 10.1016/j.ajic.2010.01.002

[13] Volodin NN, Sukhikh GT, editors. Bazovaya pomoshch’ novorozhdennomu – mezhdunarodnyy opyt. Moscow: GEOTAR-Media; 2008. 208 p. (In Russ).

[14] Базовая помощь новорождённому — международный опыт / под ред. Н.Н. Володина, Г.Т. Сухих, Е.Н. Байбариной, И.И. Рюминой. Москва: ГЭОТАР-Медиа, 2008. 208 с.

[15] Chajidis AK, editor. Pediatricheskiy i neonatal’nyy formulyar lekarstvennykh sredstv (detskii mnogoprofil’nyi statsionar): guidelines for healthcare managers and physicians. Saint Petersburg: GEU; 2020. 382 p. (In Russ).

[16] Педиатрический и неонатальный формуляр лекарственных средств (детский многопрофильный стационар). Методические рекомендации для организаторов здравоохранения и врачей, выпуск VII / под ред. А.К. Хаджидиса. Санкт-Петербург: ГЭУ, 2020. 382 с.

[17] Forbes GB, Forbes GM. Silver nitrate and the eyes of the newborn: crede contribution to preventive medicine. Am J Dis Child. 1971;121(1):1–3. doi: 10.1001/archpedi.1971.02100120037001

[18] Forbes G.B., Forbes G.M. Silver nitrate and the eyes of the newborn: crede contribution to preventive medicine // Am J Dis Child. 1971. Vol. 121, N 1. P. 1–3. doi: 10.1001/archpedi.1971.02100120037001

[19] Plotzko E, Bowman L, Abelson M, et al. Clinical Study Group Phase 3 safety comparisons for 1,5% azithromycin in polymeric mucoadhesive eye drops versus 0,3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48(8):3425–3429. doi: 10.1167/iovs.06-1413

[20] Plotzko E., Bowman L., Abelson M., et al. Clinical Study Group Phase 3 safety comparisons for 1,5% azithromycin in polymeric mucoadhesive eye drops versus 0,3% tobramycin eye drops for bacterial conjunctivitis // Invest Ophthalmol Vis Sci. 2007. Vol. 48, N 8. P. 3425–3429. doi: 10.1167/iovs.06-1413

[21] Red Book: report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. 1151 p.

[22] Red Book: report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2015. 1151 p.

[23] Galeeva GZ, Samoylov AN, Musina LT. The differential approach to the treatment of various clinical forms of dacryocystitis in newborn infants. Russian pediatric ophthalmology. 2013;(2):22–26. (In Russ).

[24] Галеева Г.З., Самойлов А.Н., Мусина Л.Т. Дифференцированный подход к лечению различных клинических форм дакриоцистита новорождённых // Российская педиатрическая офтальмология. 2013. № 2. С. 22–26.

[25] Evsyukova II. Vnutriutrobnaya khlamidiynaya infektsiya (diagnostika, klinika, lechenie). Saint Petersburg; 2007. 44 p. (In Russ).

[26] Евсюкова И.И. Внутриутробная хламидийная инфекция (диагностика, клиника, лечение). Санкт-Петербург, 2007. С. 1–44.

[27] Maychuk YuF. Kon”yunktivity. Sovremennaya lekarstvennaya terapiya: a guide for doctors. Moscow; 2014. 56 p. (In Russ).

[28] Майчук Ю.Ф. Конъюнктивиты. Современная лекарственная терапия. Пособие для врачей. Москва, 2014. 56 с.

[29] Katargina LA, Saidasheva EI. Kon”yunktivity novorozhdennykh. In: Ivanov DO, editor. Rukovodstvo po perinatologii. 2nd ed. Saint Petersburg: Inform-Navigator; 2019. 1592 p. (In Russ).

[30] Катаргина Л.А., Сайдашева Э.И. Конъюнктивиты новорождённых. В кн.: Руководство по перинатологии / под ред. Д.О. Иванова. 2-е изд. Санкт-Петербург: Информ-Навигатор, 2019. 1592 с.

[31] Saidasheva EI, Buyanovskaya SV, Kovshov FV, et al. The application of modern fluoroquinilones for the treatment of bacterial eye infections in the young children. Russian pediatric ophthalmology. 2015;(1):22–25. (In Russ).

[32] Сайдашева Э.И., Буяновская С.В., Ковшов Ф.В., и др. Современные фторхинолоны в терапии бактериальных инфекций глаз у детей раннего возраста // Российская педиатрическая офтальмология. 2015. № 1. С. 22–25.

[33] Vorontsova TN, Brzheskiy VV, Mikchailova MV. Microflora of conjunctiva in children and its sensitivity and resistance to antibacterial drugs. Ophthalmology in Russia. 2012;9(1):83–91. (In Russ). doi: 10.18008/1816-5095-2012-1-83-91

[34] Воронцова Т.Н., Бржеский В.В., Михайлова М.В. Чувствительность и резистентность к антибактериальным препаратам микрофлоры конъюнктивальной полости у детей // Офтальмология. 2012. № 9. С. 83–91. doi: 10.18008/1816-5095-2012-1-83-91

[35] Gusarevich OG, Aleksandrova SE. Safety and efficacy of “Azidrop” eye drops in treatment of bacterial conjunctivitis in newborn children. Ophthalmology Journal. 2015;8(3):83–83. (In Russ). doi: 10.17816/OV2015383-85

[36] Гусаревич О.Г., Александрова С.Е. Безопасность и эффективность глазных капель «Азидроп» при лечении бактериальных конъюнктивитов у новорождённых детей // Офтальмологические ведомости. 2015. T. 8, № 3. С. 83–83. doi: 10.17816/OV2015383-85

[37] Lessa FS, Edwards JR, Fridkin SK, et al. Trends in incidence of late-onset methicillin-resistant Staphylococcus aureus intensive care units: data from the National Nosocomial Infections Surveillance System, 1995-2004. Pediatr Infect Dis J. 2009;28(7):577–581. doi: 10.1097/INF.0b013e31819988bf

[38] Lessa F.S., Edwards J.R., Fridkin S.K., et al. Trends in incidence of late-onset methicillin-resistant Staphylococcus aureus intensive care units: data from the National Nosocomial Infections Surveillance System, 1995-2004 // Pediatr Infect Dis J. 2009. Vol. 28, N 7. P. 577–581. doi: 10.1097/INF.0b013e31819988bf

[39] Bremond-Gignac D, Nezzar H, Bianchi PE, et al. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. Br J Ophthalmol. 2014;98(6):739–745. doi: 10.1136/bjophthalmol-2013-303888

[40] Bremond-Gignac D., Nezzar H., Bianchi P.E. et al. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis // Br J Ophthalmol. 2014. Vol. 98, N 6. P. 739–745. doi: 10.1136/bjophthalmol-2013-303888

RIGHTS & PERMISSIONS

Eco-Vector